Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome

被引:30
|
作者
Alpanes, Macarena
Luque-Ramirez, Manuel
Angeles Martinez-Garcia, M.
Fernandez-Duran, Elena
Alvarez-Blasco, Francisco
Francisco Escobar-Morreale, Hector
机构
[1] Univ Alcala, Hosp Univ Ramon y Cajal, IRYCIS, Dept Endocrinol & Nutr,Diabet Obes & Human Reprod, Madrid, Spain
[2] Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain
关键词
Androgen excess; dehydroepiandrosterone sulfate; glucose tolerance; insulin sensitivity; insulin resistance; obesity; DEHYDROEPIANDROSTERONE-SULFATE; ANDROGEN EXCESS; INSULIN-RESISTANCE; PREVALENCE; TESTOSTERONE; PARAMETERS; SOCIETY; PCOS; HYPERINSULINEMIA; ASSOCIATION;
D O I
10.1016/j.fertnstert.2014.12.105
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To study the impact of adrenal hyperandrogenism (AH; defined as DHEAS concentration >95th percentile of a healthy female control population) on cardiometabolic risk factors associated with polycystic ovary syndrome (PCOS). Design: Cross-sectional study. Setting: Academic hospital. Patient(s): Two-hundred ninety-eight consecutive women with PCOS, of whom 120 were obese (body mass index [BMI] >= 30 kg/m(2)) and 178 nonobese (BMI <30 kg/m(2)). Intervention(s): None. Main Outcome Measure(s): Comprehensive evaluation of cardiovascular risk factors, including 75-g oral glucose tolerance test, office blood pressure, lipid profile, and low-grade inflammatory markers. Result(s): Patients with AH (AH-PCOS) had higher insulin circulating levels and lower insulin sensitivity than their counterparts without AH (non-AH-PCOS). Obesity, but not AH, was the main contributor to the presence of glucose tolerance disorders. Both obesity and AH increased the prevalence of prehypertension and hypertension. AH diminished high-density lipoprotein (HDL) levels in nonobese PCOS women in parallel with a decrease in total cholesterol levels, leading to a total to HDL cholesterol ratio similar to that of nonobese non-AH-PCOS patients. Furthermore, AH blunted the deleterious effect of obesity on the total cholesterol/HDL ratio, with the ratio of obese AH-PCOS patients being similar to that of nonobese PCOS patients with or without AH. Conclusion(s): The presence of AH in women with PCOS is associated with reduced insulin sensitivity and increased blood pressure but may have beneficial impact on the lipid profile. Obesity is the main determinant of the clustering of cardiovascular risk factors in PCOS women. ((c) 2015 by American Society for Reproductive Medicine.)
引用
收藏
页码:795 / U519
页数:9
相关论文
共 50 条
  • [41] Influence of metformin on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials
    Fontes, Adriana F. S.
    Reis, Fernando M. M.
    Candido, Ana Lucia
    Gomes, Karina B.
    Tosatti, Jessica A. G.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 79 (04) : 445 - 460
  • [42] Influence of metformin on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials
    Adriana F. S. Fontes
    Fernando M. Reis
    Ana Lúcia Cândido
    Karina B. Gomes
    Jéssica A. G. Tosatti
    European Journal of Clinical Pharmacology, 2023, 79 : 445 - 460
  • [43] Adrenal Androgen Predictive Effects on Clinical and Metabolic Abnormalities of Polycystic Ovary Syndrome
    de Medeiros, Sebastiao Freitas
    Barbosa, Bruna Barcelo
    Souto de Medeiros, Matheus Antonio
    Lin Winck Yamamoto, Ana Karine
    Winck Yamamoto, Marcia Marly
    REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA, 2022, 44 (02): : 142 - 153
  • [44] Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome
    Kolodziejczyk, B
    Duleba, AJ
    Spaczynski, RZ
    Pawelczyk, L
    FERTILITY AND STERILITY, 2000, 73 (06) : 1149 - 1154
  • [45] Cardiovascular, anthropometric, metabolic and hormonal profiling of normotensive women with polycystic ovary syndrome with and without biochemical hyperandrogenism
    Małgorzata Kałużna
    Tomasz Krauze
    Katarzyna Ziemnicka
    Katarzyna Wachowiak-Ochmańska
    Jolanta Kaczmarek
    Adam Janicki
    Andrzej Wykrętowicz
    Marek Ruchała
    Przemysław Guzik
    Endocrine, 2021, 72 : 882 - 892
  • [46] Hyperandrogenism and polycystic ovary syndrome in women with type 1 diabetes mellitus
    Codner, Ethel
    Escobar-Morreale, Hector F.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (04): : 1209 - 1216
  • [47] Hyperandrogenism and hyperinsulinism in children of women with polycystic ovary syndrome: A controlled study
    Kent, Sarah C.
    Gnatuk, Carol L.
    Kunselman, Allen R.
    Demers, Laurence M.
    Lee, Peter A.
    Legro, Richard S.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (05): : 1662 - 1669
  • [48] Clinical and metabolic characteristics of polycystic ovary syndrome without polycystic ovary: a pilot study on Chinese women
    Shi, Yuhua
    Gao, Xuan
    Sun, Xuedong
    Zhang, Peng
    Chen, Zijiang
    FERTILITY AND STERILITY, 2008, 90 (04) : 1139 - 1143
  • [49] Cardiovascular, anthropometric, metabolic and hormonal profiling of normotensive women with polycystic ovary syndrome with and without biochemical hyperandrogenism
    Kaluzna, Malgorzata
    Krauze, Tomasz
    Ziemnicka, Katarzyna
    Wachowiak-Ochmanska, Katarzyna
    Kaczmarek, Jolanta
    Janicki, Adam
    Wykretowicz, Andrzej
    Ruchala, Marek
    Guzik, Przemyslaw
    ENDOCRINE, 2021, 72 (03) : 882 - 892
  • [50] The polycystic ovary syndrome phenotype modulates prevalence of the metabolic syndrome
    Tan, S.
    Hahn, S.
    Sack, S.
    Benson, S.
    Elsenbruch, S.
    Schmidt, M.
    Kimmig, R.
    Erbel, R.
    Mann, K.
    Janssen, O. E.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2007, 115 : S19 - S19